Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000677003 | SCV002487003 | benign | not provided | 2023-11-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002531382 | SCV003529032 | uncertain significance | Inborn genetic diseases | 2021-08-17 | criteria provided, single submitter | clinical testing | The c.244A>G (p.N82D) alteration is located in exon 2 (coding exon 2) of the MRPL44 gene. This alteration results from a A to G substitution at nucleotide position 244, causing the asparagine (N) at amino acid position 82 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000677003 | SCV005242705 | benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000677003 | SCV000802832 | uncertain significance | not provided | 2016-02-26 | no assertion criteria provided | clinical testing |